The WACC of Marinomed Biotech AG (MARI.VI) is 6.8%.
| Range | Selected | |
| Cost of equity | 5.10% - 11.20% | 8.15% |
| Tax rate | 0.10% - 0.10% | 0.10% |
| Cost of debt | 4.00% - 7.00% | 5.50% |
| WACC | 4.5% - 9.1% | 6.8% |
| Category | Low | High |
| Long-term bond rate | 2.8% | 3.3% |
| Equity market risk premium | 5.7% | 6.7% |
| Adjusted beta | 0.4 | 1.12 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 5.10% | 11.20% |
| Tax rate | 0.10% | 0.10% |
| Debt/Equity ratio | 0.99 | 0.99 |
| Cost of debt | 4.00% | 7.00% |
| After-tax WACC | 4.5% | 9.1% |
| Selected WACC | 6.8% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for MARI.VI:
cost_of_equity (8.15%) = risk_free_rate (3.05%) + equity_risk_premium (6.20%) * adjusted_beta (0.4) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.